Key result
Edoxaban matches warfarin efficacy for thromboembolism while reducing bleeding risk in AF and VTE.
Why the study?
Does edoxaban provide effective and safe anticoagulation for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism compared to standard therapy?
Does edoxaban provide effective and safe anticoagulation for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism compared to standard therapy?
Edoxaban is an effective and safe once-daily direct oral anticoagulant that broadens options for modern anticoagulation management.
Answers are grounded in this paper and cite their sources.
Edoxaban may be preferred over warfarin for AF and VTE to lower bleeding; leaves open head-to-head comparisons with other NOACs in real-world cohorts.
Edoxaban is a direct factor Xa inhibitor and has become the fourth direct oral anticoagulant (DOAC) approved for stroke prevention in atrial fibrillation (AF) and for treatment and secondary prevention of venous thromboembolism (VTE). This review provides an overview of the key characteristics of edoxaban and clinical evaluation program leading to regulatory approval. Approval for AF and VTE treatment was based on large phase III randomized controlled trials that showed that edoxaban reduces the risk of bleeding compared with warfarin and provides similar protection against thromboembolism. Edoxaban is the second once-daily DOAC, is tested in a reduced dose for patients with a moderate renal impairment, body weight of ≤60 kg or concomitant use of p-glycoprotein inhibitors and thereby is a valuable addition to the therapeutic arsenal of modern anticoagulation. For AF regulatory approval in the USA is limited to patients with a creatinine clearance of 15-95 ml/min. Another limitation is the need for initial parenteral anticoagulation with heparin in treatment of acute VTE.
No takes yet. Share an insight, caveat, or question.
Brekelmans et al. (2015) conducted a review in Atrial fibrillation and venous thromboembolism. Edoxaban vs. Warfarin or low-molecular-weight heparin was evaluated. Edoxaban provides similar protection against thromboembolism and reduces the risk of bleeding compared with warfarin in patients with atrial fibrillation and venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: